Skip to main content

Table 1 Neutralization profile of patient ITM4 in a primary virus/PBMC assay (left) and a pseudovirus/TZM-bl assay (right)

From: Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies

 

PBMC/Primary Virus Assay

Plasma Sample ITM4_05

Pseudovirus/TZM bl Assay

Plasma Sample ITM4_07

Subtype

Virus

% Neutralizationa

Pseudovirus

ID50b

A

VI 191

66

PV 92RW009

222

 

92UG037

100

PV PIC 32281

54

 

VI 820

99

  
 

VI 1031

100

  

B

89.6

0

PV SF162

322

 

93US076

69

PV JRFL

88

 

93US077

97

PV AC10

62

 

93US143

100

PV CAAN

33

C

VI 829

80

PV VI 829

180

 

VI 882

99

PV VI 882

316

 

VI 1358

99

PV VI 1358

208

 

VI 1144

100

PV 92BR025

155

   

PV Du174

333

D

VI 656

97

PV UG024

>640

 

VI 693

100

  
 

VI 824

91

  
 

VI 865

93

  

CRF01

VI 1249

98

PV CM244

93

 

CA 10

97

  
 

VI 1888

96

  
 

92TH022

99

  

CRF02

VI 1090

94

PV VI 1090

221

 

CA18

88

PV CA18

63

 

VI 2680

99

  
 

VI 1380

98

  
 

VI 2727

93

  
  1. a % neutralization obtained with 1:20 plasma dilution, ≥80% reduction in virus titer is indicated in bold.
  2. b Plasma dilution causing 50% reduction of relative light units compared to the virus control, ID50 ≥50 is indicated in bold.